Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00534417 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
A Phase 2 study of Metastatic Breast Cancer, sponsored by Accelerated Community Oncology Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 10
- Study locations
NCT00534417 is a Phase 2 study of Metastatic Breast Cancer that has completed, run by Accelerated Community Oncology Research Network. The registered enrollment target is 41 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (80% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT00534417, a Phase 2 study of Metastatic Breast Cancer, has completed, sponsored by Accelerated Community Oncology Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to determine if the combination of continuous daily capecitabine with fulvestrant on a loading dose schedule will delay disease progression in metastatic breast cancer (MBC) patients.
Conditions Studied
Interventions
- DRUG fulvestrant
- DRUG capecitabine
Study Locations (10)
Georgia
- Northeast Georgia Cancer Care - Athens
- Augusta Oncology Associates - Augusta
Illinois
- Medical & Surgical Specialists - Galesburg
- Oncology Specialists - Park Ridge
Florida
- Advanced Medical Specialties - Miami
Montana
- Hematology Oncology Centers of the Northern Rockies - Billings
Nevada
- Las Vegas Cancer Center - Henderson
Pennsylvania
- The Lancaster Cancer Center, Ltd - Lancaster
Tennessee
- The West Clinic - Memphis
Virginia
- Cancer Specialists of Tidewater - Chesapeake
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2007-10 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00534417
The ClinicalTrials.gov registry entry for NCT00534417 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (80% lower). The listed sponsor is Accelerated Community Oncology Research Network, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which fulvestrant is the first listed.
NCT00534417 reports 10 study locations spanning 8 distinct geographic areas - top geographies include Georgia, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT00534417 about?
NCT00534417 is a clinical study titled "Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer". The purpose of this study is to determine if the combination of continuous daily capecitabine with fulvestrant on a loading dose schedule will delay disease progression in metastatic breast cancer (MBC) patients.
What is the current status of trial NCT00534417?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2007-10. Estimated completion is 2011-09.
What conditions does trial NCT00534417 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT00534417?
The interventions under investigation include: fulvestrant (DRUG), capecitabine (DRUG).
Who is sponsoring clinical trial NCT00534417?
This trial is sponsored by Accelerated Community Oncology Research Network, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00534417 being conducted?
This trial has 10 study locations across Florida, Georgia, Illinois, Montana, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
A Study of Surgery and Radiotherapy in People With Breast Cancer
RECRUITING · Phase 2
-
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
RECRUITING · Phase 2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.